- Home
- EHAB vs MAZE Comparison
EHAB vs MAZE Comparison
Compare EHAB & MAZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHAB
- MAZE
- Stock Information
- Founded
- EHAB 2014
- MAZE 2018
- Country
- EHAB United States
- MAZE United States
- Employees
- EHAB N/A
- MAZE N/A
- Industry
- EHAB Hospital/Nursing Management
- MAZE
- Sector
- EHAB Health Care
- MAZE
- Exchange
- EHAB Nasdaq
- MAZE NYSE
- Market Cap
- EHAB 401.6M
- MAZE 367.0M
- IPO Year
- EHAB N/A
- MAZE 2025
- Fundamental
- Price
- EHAB $7.07
- MAZE $15.74
- Analyst Decision
- EHAB Buy
- MAZE Strong Buy
- Analyst Count
- EHAB 2
- MAZE 4
- Target Price
- EHAB $8.75
- MAZE $23.50
- AVG Volume (30 Days)
- EHAB 810.2K
- MAZE 127.1K
- Earning Date
- EHAB 08-05-2025
- MAZE 08-14-2025
- Dividend Yield
- EHAB N/A
- MAZE N/A
- EPS Growth
- EHAB N/A
- MAZE N/A
- EPS
- EHAB N/A
- MAZE 0.34
- Revenue
- EHAB $1,032,300,000.00
- MAZE $167,500,000.00
- Revenue This Year
- EHAB $4.66
- MAZE N/A
- Revenue Next Year
- EHAB $4.99
- MAZE N/A
- P/E Ratio
- EHAB N/A
- MAZE $45.91
- Revenue Growth
- EHAB N/A
- MAZE N/A
- 52 Week Low
- EHAB $6.85
- MAZE $6.71
- 52 Week High
- EHAB $10.91
- MAZE $17.00
- Technical
- Relative Strength Index (RSI)
- EHAB 21.84
- MAZE N/A
- Support Level
- EHAB $7.07
- MAZE N/A
- Resistance Level
- EHAB $7.54
- MAZE N/A
- Average True Range (ATR)
- EHAB 0.36
- MAZE 0.00
- MACD
- EHAB -0.18
- MAZE 0.00
- Stochastic Oscillator
- EHAB 7.75
- MAZE 0.00
About EHAB Enhabit Inc.
Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing an advanced, life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.